RU2763787C2 - Стабильные водные составы на основе антител - Google Patents

Стабильные водные составы на основе антител Download PDF

Info

Publication number
RU2763787C2
RU2763787C2 RU2016119755A RU2016119755A RU2763787C2 RU 2763787 C2 RU2763787 C2 RU 2763787C2 RU 2016119755 A RU2016119755 A RU 2016119755A RU 2016119755 A RU2016119755 A RU 2016119755A RU 2763787 C2 RU2763787 C2 RU 2763787C2
Authority
RU
Russia
Prior art keywords
antibody
variable region
chain variable
formulation
particles
Prior art date
Application number
RU2016119755A
Other languages
English (en)
Russian (ru)
Other versions
RU2016119755A3 (enExample
RU2016119755A (ru
Inventor
Уилльям ЛИЧ
Рейчел ЛЬЮУС
Джеймс МАКДЖИВНИ
Келси НЬЮЭЛЛ
Кевин Дуглас СТЮАРТ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2016119755A publication Critical patent/RU2016119755A/ru
Publication of RU2016119755A3 publication Critical patent/RU2016119755A3/ru
Application granted granted Critical
Publication of RU2763787C2 publication Critical patent/RU2763787C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
RU2016119755A 2013-10-24 2014-10-23 Стабильные водные составы на основе антител RU2763787C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361895143P 2013-10-24 2013-10-24
US61/895,143 2013-10-24
PCT/US2014/061997 WO2015061584A1 (en) 2013-10-24 2014-10-23 Stable, aqueous antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021137159A Division RU2021137159A (ru) 2013-10-24 2014-10-23 Стабильные водные составы на основе антител

Publications (3)

Publication Number Publication Date
RU2016119755A RU2016119755A (ru) 2017-11-27
RU2016119755A3 RU2016119755A3 (enExample) 2018-04-28
RU2763787C2 true RU2763787C2 (ru) 2022-01-11

Family

ID=52993565

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016119755A RU2763787C2 (ru) 2013-10-24 2014-10-23 Стабильные водные составы на основе антител
RU2021137159A RU2021137159A (ru) 2013-10-24 2014-10-23 Стабильные водные составы на основе антител

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2021137159A RU2021137159A (ru) 2013-10-24 2014-10-23 Стабильные водные составы на основе антител

Country Status (23)

Country Link
US (4) US20150118249A1 (enExample)
EP (2) EP3892288A1 (enExample)
JP (3) JP6483673B2 (enExample)
KR (3) KR20210041101A (enExample)
CN (4) CN105611938B (enExample)
AU (4) AU2014339984B2 (enExample)
BR (1) BR112016008576B1 (enExample)
CA (1) CA2926089C (enExample)
CY (1) CY1125697T1 (enExample)
DK (1) DK3060229T3 (enExample)
ES (1) ES2893861T3 (enExample)
HR (1) HRP20211371T1 (enExample)
HU (1) HUE055919T2 (enExample)
LT (1) LT3060229T (enExample)
MX (2) MX388893B (enExample)
PL (1) PL3060229T3 (enExample)
PT (1) PT3060229T (enExample)
RS (1) RS62419B1 (enExample)
RU (2) RU2763787C2 (enExample)
SG (2) SG10201803178UA (enExample)
SI (1) SI3060229T1 (enExample)
SM (1) SMT202100580T1 (enExample)
WO (1) WO2015061584A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
AU2013256229A1 (en) * 2012-05-03 2014-10-30 Medimmune, Llc Method for analyzing sample components
TWI660972B (zh) 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations
CA2938933A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
ES2744526T3 (es) 2014-03-12 2020-02-25 Prothena Biosciences Ltd Anticuerpos anti-MCAM y métodos de uso asociados
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
EP4606820A3 (en) * 2015-11-30 2025-10-29 Medimmune, LLC Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
ES2968923T3 (es) 2016-08-10 2024-05-14 Celltrion Inc Preparación farmacéutica líquida estable de anticuerpo contra el virus de la gripe
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
CA3080656A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
IL280880B2 (en) 2018-08-27 2025-04-01 Regeneron Pharma Using Raman Spectroscopy in Downstream Purification
MX2021009851A (es) 2019-02-18 2021-09-10 Lilly Co Eli Formulacion de anticuerpos terapeuticos.
CN113507938B (zh) * 2019-03-29 2024-04-16 广东恒瑞医药有限公司 包含抗il-5抗体的药物组合物及其用途
TW202126688A (zh) 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
JP7718272B2 (ja) * 2019-12-16 2025-08-05 ニプロ株式会社 凝集防止剤ならびにそれを用いた医薬組成物および医療用デバイス
CN111024963A (zh) * 2019-12-27 2020-04-17 桂林英美特生物技术研究所 一种液体稳定、抗冰冻的免疫比浊法载脂蛋白b单试剂
KR20220152540A (ko) * 2020-03-13 2022-11-16 삼성바이오에피스 주식회사 안정성이 증진된 액상 약제학적 조성물
CN113769081A (zh) * 2020-06-10 2021-12-10 三生国健药业（上海）股份有限公司 一种稳定的高浓度抗人il-5单克隆抗体液体制剂
CA3204307A1 (en) * 2020-12-17 2022-06-23 Astrazeneca Ab Anti-il5r antibody formulations

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2314130C2 (ru) * 2003-05-26 2008-01-10 Воо Ин БАИК Одноразовый шприц
RU2384369C1 (ru) * 2006-02-07 2010-03-20 Зарстедт Аг Унд Ко. Контейнер для проб для приема малых объемов жидкости для исследований
WO2010102241A1 (en) * 2009-03-06 2010-09-10 Genentech, Inc. Antibody formulation
RU2580012C2 (ru) * 2007-03-30 2016-04-10 Медиммун, Ллк Препарат антитела
EA028227B1 (ru) * 2011-07-28 2017-10-31 Ридженерон Фармасьютикалз, Инк. Стабилизированные составы, содержащие антитела к человеческой пропротеиновой конвертазе субтилизин/кексин типа 9 (pcsk9)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
ATE218889T1 (de) 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6018032A (en) * 1995-09-11 2000-01-25 Kyowa Hakko Kogyo Co., Ltd. Antibody against human interleukin-5-receptor α chain
JP2006502116A (ja) * 2002-07-12 2006-01-19 メダレックス， インク． タンパク質の酸化分解を防ぐ方法及び組成物
GEP20125628B (en) * 2006-04-21 2012-09-10 Novartis Ag Pharmaceutical compositions containing antagonist anti-cd40 antibody
CN101541345A (zh) * 2006-09-25 2009-09-23 米迪缪尼有限公司 稳定化的抗体制剂和其应用
DK3072525T3 (en) 2007-05-14 2018-04-30 Astrazeneca Ab PROCEDURES FOR REDUCING BASOFILE CELL LEVELS
SG2014011365A (en) * 2008-09-19 2014-05-29 Hoffmann La Roche Novel antibody formulation
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
BR112014009031A2 (pt) * 2011-10-18 2017-05-09 Coherus Biosciences Inc formulações de etanercept estabilizadas com íons de metais
EP2771358A4 (en) * 2011-10-26 2015-08-26 Bio Rad Laboratories ELIMINATION OF VIRAL AGENTS IN MIXED MODE CHROMATOGRAPHY
CA2951856A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
US20140328839A1 (en) * 2011-11-01 2014-11-06 Medlmmune, Llc Methods For Reducing The Frequency And Severity Of Acute Exacerbations Of Asthma
KR102337599B1 (ko) * 2013-08-12 2021-12-10 아스트라제네카 아베 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법
WO2015023504A1 (en) * 2013-08-12 2015-02-19 Medlmmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
EP3892288A1 (en) * 2013-10-24 2021-10-13 Astrazeneca AB Stable, aqueous antibody formulations

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2314130C2 (ru) * 2003-05-26 2008-01-10 Воо Ин БАИК Одноразовый шприц
RU2384369C1 (ru) * 2006-02-07 2010-03-20 Зарстедт Аг Унд Ко. Контейнер для проб для приема малых объемов жидкости для исследований
RU2580012C2 (ru) * 2007-03-30 2016-04-10 Медиммун, Ллк Препарат антитела
WO2010102241A1 (en) * 2009-03-06 2010-09-10 Genentech, Inc. Antibody formulation
EA028227B1 (ru) * 2011-07-28 2017-10-31 Ридженерон Фармасьютикалз, Инк. Стабилизированные составы, содержащие антитела к человеческой пропротеиновой конвертазе субтилизин/кексин типа 9 (pcsk9)

Also Published As

Publication number Publication date
CN105611938B (zh) 2024-12-31
CN105611938A (zh) 2016-05-25
AU2022291595B2 (en) 2025-06-12
LT3060229T (lt) 2021-09-27
JP2019116480A (ja) 2019-07-18
AU2014339984A1 (en) 2016-04-28
AU2022291595A1 (en) 2023-03-16
CA2926089C (en) 2022-08-30
MX2021015825A (es) 2022-02-03
HUE055919T2 (hu) 2022-01-28
KR20210041101A (ko) 2021-04-14
BR112016008576B1 (pt) 2023-03-07
BR112016008576A2 (pt) 2017-10-03
CN113350278B (zh) 2023-03-24
RU2021137159A (ru) 2022-01-11
SG10201803178UA (en) 2018-05-30
US20200297855A1 (en) 2020-09-24
KR20160068946A (ko) 2016-06-15
CA2926089A1 (en) 2015-04-30
EP3892288A1 (en) 2021-10-13
ES2893861T3 (es) 2022-02-10
PT3060229T (pt) 2021-10-07
PL3060229T3 (pl) 2021-12-27
RU2016119755A3 (enExample) 2018-04-28
KR102238065B1 (ko) 2021-04-07
KR102109053B1 (ko) 2020-05-13
JP2021152034A (ja) 2021-09-30
HK1221900A1 (zh) 2017-06-16
AU2014339984B2 (en) 2020-04-09
CN113350278A (zh) 2021-09-07
AU2025230794A1 (en) 2025-10-02
JP2016535020A (ja) 2016-11-10
US20150118249A1 (en) 2015-04-30
EP3060229B1 (en) 2021-08-25
JP6896781B2 (ja) 2021-06-30
MX388893B (es) 2025-03-20
KR20200051844A (ko) 2020-05-13
AU2020204608A1 (en) 2020-07-30
CN119971024A (zh) 2025-05-13
US20250170245A1 (en) 2025-05-29
CN112107538A (zh) 2020-12-22
JP6483673B2 (ja) 2019-03-13
EP3060229A4 (en) 2017-08-16
SG11201603206UA (en) 2016-05-30
WO2015061584A1 (en) 2015-04-30
RS62419B1 (sr) 2021-10-29
EP3060229A1 (en) 2016-08-31
MX2016004605A (es) 2016-11-14
HRP20211371T1 (hr) 2021-11-26
RU2016119755A (ru) 2017-11-27
SI3060229T1 (sl) 2021-11-30
US20190201535A1 (en) 2019-07-04
DK3060229T3 (da) 2021-10-11
CY1125697T1 (el) 2024-02-16
SMT202100580T1 (it) 2021-11-12

Similar Documents

Publication Publication Date Title
RU2763787C2 (ru) Стабильные водные составы на основе антител
JP2022066345A (ja) 安定な抗ｉｆｎａｒ１製剤
AU2013334740A1 (en) Stable, low viscosity antibody formulation
TWI764097B (zh) 包含抗ｃｄ４７抗體的製劑及其製備方法和用途
HK40060962A (en) Stable, aqueous antibody formulations
HK40061789B (en) Stable, aqueous antibody formulations
HK40061789A (en) Stable, aqueous antibody formulations
HK40042589A (en) Stable, aqueous antibody formulations
HK1227741B (en) Stable, aqueous antibody formulations